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Summary Ki67 immunostaining has been performed on 136 primary breast cancers and related to various
clinical and pathological features of the disease. Staining was most frequently seen in poorly differentiated
tumours showing high rates of mitotic activity, but was independent of tumour size, lymph-node status and
ER expression. A high level of Ki67 immunostaining was often associated with early recurrence of breast
cancer after mastectomy. These data are consistent with the concept of the Ki67 antibody detecting an
antigen that is closely related to cell proliferation and thus provides a clinically useful marker for this
important characteristic of the tumour.
The growth of breast cancer is highly variable. This is
reflected in its clinical course and is a major factor
contributing to prognosis. To date, however, methods
employed to assess this parameter have had limited success.
The opportunity to monitor the clinical growth of primary
and metastatic tumours directly occurs infrequently (see
Devitt, 1983) and more indirect methods of 3H thymidine
incorporation (Silvestrini et al., 1974) or flow cytometry
(Haag et al., 1984) are complex procedures that are time
consuming and not really applicable to routine clinical
samples. More recently, a monoclonal antibody Ki67 has
been produced which is suggested to react with a nuclear
antigen present throughout the cell cycle (GI, S, G2 and M
phases) of proliferating cells, but is absent in quiescent (GO)
cells (Gerdes et al., 1984a, b). This antibody can be readily
used in an immunocytochemical assay (Gerdes et al., 1986)
and its binding has been shown to correlate with the
histological classification of non-Hodgkin's lymphomas and
with lymph node status (Gerdes et al., 1984a, b) and
histological grade of malignancy (Barnard et al., 1987) in
breast cancers.
The current study reports our early experience with this
marker of cell proliferation in a series of 136 primary breast
cancer specimens from a single centre and its correlation
with the early recurrence of breast cancer after mastectomy.
Patients and methods
Tumour samples were obtained from 136 unselected primary
breast cancer patients at the City Hospital in Nottingham
under the care of Professor R.W. Blamey. A simple or
subcutaneous mastectomy was undertaken and lymph-node
biopsy samples were removed from the lower axilla, from the
apex of the axilla and from the internal mammary chain
(Blamey et al., 1980). Patients with tumour cells
histologically evident in any node were classified as lymph-
node positive. All patients had tumours which were judged
clinically to be less than 5cm diameter, and none showed
any evidence of distant metastases at presentation. The
menopausal status and age at mastectomy of each patient
were recorded in addition to tumour size. Histological grade
of malignancy was assessed in all tumours by C.W.E. and
I.O.E. using a modification of Bloom and Richardson's
criteria (Elston et al., 1980). Tumours were classified I to III
with increasing loss of differentiation. The mitotic activity of
tumours was assessed by counting the number of mitotic
figures in 10 or 20 high power fields around the periphery of
the tumour. The divisions I to III corresponded to 0-9, 10-
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19 and >20 mitotic figures per 10 high power fields. All
primary breast cancer patients were followed up at 3-
monthly intervals for 18 months and 6-monthly thereafter.
Recurrent disease that was palpable was confirmed
cytologically or histologically. Metastatic disease was
confirmed by clinical or radiological examination.
Tissue preparation
Immediately after surgery tumour tissue was snap frozen and
stored in liquid nitrogen before transportation to the
Tenovus Institute in dry ice. Samples were stored at -70°C
until assay, at which time a portion of the frozen tissue was
embedded in Tissue-Tek OCT (Miles Scientific, Naperville,
IL, USA) and maintained at -70°C. The remainder of the
tissue was utilised in the oestrogen receptor enzyme-
immunoassay (ER-EIA).
Antibodies and Ki67 staining procedure
Cryostat sections (5 um) were cut, mounted on slides coated
with tissue adhesive, fixed in acetone (-10 to -25°C) and
air dried. Sections were incubated at room temperature with
normal goat serum (diluted 1 in 10 with 10mm phosphate-
buffered saline (PBS; pH7.2-7.4) for 15min, excess serum
was removed and the slides were incubated for a further
45min with mouse monoclonal Ki67 antibody (1.4pgMnl-1;
Dakopatts, Denmark). The slides were then rinsed in PBS
and reincubated for 30min with a goat-antimouse bridging
antibody (4.7Mgml -1; Sigma, UK) containing normal
human serum (diluted 1 in 50 with PBS), followed, after
washing (2 x PBS), with a mouse peroxidase antiperoxidase
complex (PAP; diluted 1 in 250 with PBS; Dakopatts,
Denmark) for 30min. A chromogen substrate solution
containing hydrogen peroxide (0.06% v/v) and diamino-
benzidine 4HC1 (DAB; 0.05% w/v) was added to each
specimen for 5min. The reaction of peroxidase in the PAP
complex with hydrogen peroxide converts the DAB to a
reddish brown product. Sections were immersed in distilled
water before counterstaining with Harris's Haematoxylin
(1% v/v) for 6min. The slides were then rinsed in tapwater
for 5 min, dehydrated in alcohol, cleared in xylene and
mounted under coverslips in dibutylpthalate xylene solution.
All specimen evaluation was performed on an Olympus
microscope (BH-2) using an ocular magnification of x 40
with an eyepiece grid (Graticules Ltd, UK). Ten to 20 fields
per tumour were examined depending on its cellularity
(minimum 1,000 tumour cells). Control slides (minus primary
antibody) were assessed for non-specific binding before
assessing the percentage of tumour cell binding the Ki67
antibody. Tumours were classified as positive where greater
than 5% of tumour cells expressed detectable quantities of
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Ki67. This value was selected since it represented a figure
which is in excess of that determined for normal and benign
breast tissue. Additionally, tumours were classified as highly
positive if they contained 20% or greater of their cells
expressing Ki67 immunostaining. This value was chosen
because it selected for the highest quadrile of Ki67 values.
Areas of normal and benign breast were excluded from the
final assessment.
Oestrogen receptor enzymeimmunoassay (ER-EIA)
The enzymeimmunoassay for the detection of ER was
carried out using an assay kit developed by Abbott
Diagnostics (Abbott Laboratories, Chicago, USA). The
assay is a solid-phase immunoassay based on a sandwich
principal and has been described in detail elsewhere
(Nicholson et al., 1986). An ER-EIA value of greater or
equal to 10fmolpermg protein was taken to signify an ER-
positive tumour.
Statistical analysis
Data were analysed using x2 and x2 for trend according to
Armitage (1971). The recurrence free interval for breast
cancer patients was determined by life table analysis
(Mantel-Cox) on 124 patients who had been followed up for
greater than 3 months after mastectomy.
Results
Localisation of Ki67 in breast cancer specimens
Figure la and b shows typical immunocytochemical staining
patterns for highly Ki67 positive tumours. Staining is
presented in the nuclei of approximately 40% and 10% of
the tumour cells respectively. Of the 136 tumours examined
74 (54%) were positive for Ki67 binding (>5% tumour
nuclei stained). Both the proportion of tumour nuclei
expressing the antigen and the intensity of stain were,
however, variable (0-85% cells involved; mean value
Figure 1 Ki67 immunostaining in positive breast cancer.
12% + 1.49 s.e.m.). Antibody binding was sometimes
observed in the nuclei of normal and benign components of
the breast tumour. The proportion of nuclei involved,
however, was low (<5%) and the data are not included in
the analysis.
Association of Ki67 binding with various clinical,
pathological and biochemicalfeatures of breast cancer
An excellent correlation exists between the histological grade
of malignancy of breast tumours and their Ki67 status
(Figure 2a). Thus while only 31% (9/29) of well differen-
tiated grade I tumours were Ki67 positive (>5% tumour
nuclei stained) the corresponding values for the more poorly
differentiated grade II and III tumours were 45% (21/46)
and 72% (44/61) respectively. This trend was also reflected
in the average number of Ki67 positive tumour cells within
the individual grades of malignancy. Further subdivision of
positive samples (>5% tumour nuclei stained) into groups of
tumours showing Ki67 binding in 5-19% and >20% of their
nuclei demonstrated that the latter group comprised only
grade II and III tumours. A highly significant association
was observed between increasing numbers of Ki67 positive
cells and increasing histological grade of malignancy
(X2=21.4, P<0.001; X2 (trend)=20.6, P<0.001).
Examination of the individual components of tumour
grade and Ki67 binding showed a similar association to that
described above with Ki67 status and percentage of cells
staining, increasing with increasing nuclear abnormalities
(Figure 2b; x2 =6.9, P<0.05; x2 (trend)=6.9, P<0.05),
increasing numbers of mitotic figures present within the
periphery of the tumour (Figure 2c; X2=32.2, P<0.01; x2
(trend)=26.7, P<0.001) and loss of tubular differentiation
(Figure 2d; x2 =7.4, P<0.05, x2 (trend)=26.7, P<0.1).
No significant association was observed between either
tumour size (Figure 3a), lymph-node status (Figure 3b), age
at mastectomy (Figure 3c) or menopausal status (Figure 3d)
and the Ki67 status of breast cancers (statistics not illus-
trated), although large tumours often contained an increased
number of Ki67 positive cells (>20% cells stained). Con-
versely, although the Ki67 status of breast tumours and their
percentage staining also failed to correlate significantly with
the ER-EIA status of the breast cancers (Figure 3e), ER-EIA
positive tumours contained a slightly higher proportion of
Ki67 negative tumours (46/95, 48%) than ER-EIA negative
tumours (16/40, 40%).
Recurrence-free interval
Examination of the recurrence-free interval of patients
following mastectomy showed that women with Ki67 pos-
itive tumours have a less favourable early prognosis than
those with Ki67 negative disease and suffer an increased
number of recurrences (Figure 4a). Further stratification of
the data according to the number of Ki67 positive cells
within breast tumours identified a high rate of recurrence in
patients whose tumours contained >20% Ki67 positive cells
(Figure 4b and c). High rates of recurrence were observed in
patients whose tumours expressed high amounts of Ki67
immunostaining (>20% cells stained) irrespective of their
lymph-node involvement (Figure 5a and b) or ER-EIA
status (Figure 5c and d). The differences, however, did not
reach statistical significance (not illustrated).
Discussion
Several reports have now examined the binding of Ki67 in
breast cancer specimens and have observed a significant
relationship with the histological grade of malignancy and
the mitotic activity of tumours (Barnard et al., 1987; Gerdes
et al., 1984b; Lelle et al., 1987). This association has been
confirmed in our series and extended to show, for the first
time, that the binding of the Ki67 antibody also correlatesKi67 IMMUNOSTAINING IN BREAST CANCER 945
with the early recurrence of breast cancer, specifically when
large numbers of tumour cells immunostain (>20%).
Although a number of doubts have recently been raised
concerning the precise relationship between Ki67 binding
80-
and the cell cycle (Baisch & Gerdes, 1987), our data are
consistent with Ki67 positivity measuring an aspect of cell
proliferation and tissue growth. Indeed, in a recent series of
experiments examining Ki67 binding to MCF-7 human
breast cancer cells growing in vitro, we have observed the
numbers of cells expressing the Ki67 antigen increases from
5% to 80-90% during the initial phase of exponential
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Figure 2 Relationship between Ki67 immunostaining and
tumour pathology. (a) Histological grade of malignancy (I to III
with increasing loss of features of differentiation); (b) nuclear
pleomorphism (I to III with increasing nuclear abnormalities: I
and II have been combined because of insufficient numbers of
tumours with regular nuclear features); (c) mitotic activity (I to
III with increasing mitotic figures); (d) tubular differentiation (I to
III with increasing loss of tubular differentiation; I and II have
been combined because of insufficient numbers of tumours
showing relatively normal tubular differentiation). The con-
tinuous lines indicate the two cut-off points for the assay, i.e. 5%
and 20%, while the dotted line indicates the mean value for the
groups.
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Figure 3 Relationship between Ki67 immunostaining and vari-
ous clinical and biochemical parameters. The solid lines indicate
the two cut-off points for the assay, i.e. 5% and 20%, while the
dotted line indicates the mean value for the groups.
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Figure 4 Relationship between Ki67 immunostaining and the
early recurrence of breast cancer after mastectomy. The figures in
parenthesis indicate the numbers of patients entering the study in
each group. (a) 0-0 Ki67 negative samples (<5% cells
stained), A-A Ki67 positive samples (> 5% cells stained); (b)
0 0 Ki67 negative samples, A-A 5-19% cells immuno-
stained, 0-0 >20% cells immunostained; (c) C1-C 0-19%
cells immunostained, *-* >20% cells immunostained.
growth and then falls back to 5-10% at confluence (manu-
script in preparation). In this light, the lack of an absolute
correlation between Ki67 immunostaining and mitotic
activity in our series of breast tumours (Figure 2c) is most
readily accounted for by sampling differences within the study,
in that the estimations of these parameters were not per-
formed on the same portion of the tumour (see Materials
and methods). In a smaller series of primary breast tumours
from the Tenovus/Nottingham series where this has been
carried out, a much closer correlation has been achieved
(I.O. Ellis, personal communication).
Interestingly, although similar results to those described
above have also been observed using S phase measurements
by thymidine labelling (Mayer & Lee, 1980; Tubiana et al.,
1981; Meyer et al., 1983; Haag et al., 1984) and cell cycle
analysis by flow cytometry (Kallioniemi et al., 1988) with
high rates of cell proliferation being associated with a high
proportion of short-term relapses, Ki67 immunostaining is
much easier to perform than the above techniques and is
more suitable for routine use provided that facilities for
producing frozen sections are available.
The comparison of Ki67 binding with the important
prognostic variable lymph-node staging did not reveal any
major association. This result complements the study of
Barnard et al. (1987), but is at slight variance with the data
of Lelle et al. (1987), who suggested that the average number
of Ki67 positive cells in breast tumours was slightly higher in
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Figure 5 Relationship between Ki67 immunostaining and the
early recurrence of breast cancer after mastectomy: influence of
patient lymph-node status (a and b) and tumour ER status (c and
d).
women with lymph-node metastases. Although the reasons
for these discrepancies are not clear, other reports using
thymidine labelling have failed to show a strong correlation
between cell kinetics and lymph-node involvement (Mayer et
al., 1982; Tubiana et al., 1981). Similarly, Ki67 did not
significantly correlate with either tumour size, ER-EIA sta-
tus, age at mastectomy or menopausal status. Large tumours
did, however, tend to contain a disproportionately high
number of neoplasms with >20% Ki67 positive tumour
cells. Conversely, it is also evident that while 60% (24/40) of
ER-EIA negative tumours are Ki67 positive, this value fell
to 51% (49/95) in patients with ER-EIA positive disease and
as such is consistent with other studies reporting a high S-
phase thymidine labelling rate in ER negative breast cancers
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(Cooke, 1982). Interestingly, using a bivariate analysis,
Meyer et al. (1983) suggested that the prognostic relevance
of ER in predicting the course of the disease following
mastectomy was largely dependent on its relationship to
proliferative activity, a conclusion also reached by Nicholson
et al. (1984) examining the prognostic value of mitotic
activity and ER. In this context, it may be significant that
while the above studies employed a ligand binding assay
(LBA) to detect ER, the current study utilises a highly
sensitive enzymeimmunoassay which, although correlating
with the LBA (Leclerq et al., 1986), produces a higher ER
positivity rate (Nicholson et al., 1986).
The independence of Ki67 binding and lymph-node stag-
ing and tumour size, together with its strong relationship
with histological grade of malignancy, may ultimately allow
its substitution for the latter characteristic in a prognostic
index developed by our group to accurately predict the course
of breast cancer in subgroups of patients (Haybittle et al.,
1982). Because of the very variable nature of breast cancer it
is clinically useful to regard it as comprising subgroups of
patients, some with good prognosis, others with poor pro-
gnosis. Since an important determinant of this is undoub-
tedly the rate of growth of the disease and since sensitivity to
hormone and cytotoxic therapy may also be influenced by
this feature (Valeriote & Van Putten, 1975), Ki67 binding, as
an objective measurement of cell proliferation, should signifi-
cantly aid in the management of the breast cancer patient.
Studies to extend this series and compare Ki67 immunostain-
ing with other prognostic variables are currently underway.
The authors wish to thank the Tenovus Organisation for generous
financial support. Mr N. Bouzubar is the recipient of a Kuwait Civil
Service Commission scholarship.
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